Michael Chorny

faculty photo
Research Professor of Pediatrics
Member, Institute of Translational Medicine and Therapeutics, University of Pennsylvania
Associate Director, Center for Targeted Therapeutics & Translational Nanomedicine, Institute of Translational Medicine & Therapeutics, University of Pennsylvania
Member, Penn Medicine Cardiovascular Institute, University of Pennsylvania
Member, Center for Childhood Cancer Research, The Children’s Hospital of Philadelphia Research Institute
Associate Member, Pediatric Oncology Program, Abramson Cancer Center, University of Pennsylvania
Department: Pediatrics

Contact information
The Abramson Pediatric Research Center, Suite 702G
The Children's Hospital of Philadelphia
3615 Civic Center Blvd.
Philadelphia, PA 19104
Office: 215-590-3063
Education:
BPharm (Pharmaceutical sciences)
The Hebrew University of Jerusalem, Israel, 1996.
MS (Pharmaceutical sciences)
The Hebrew University of Jerusalem, Israel, 1997.
PhD (Pharmaceutical sciences)
The Hebrew University of Jerusalem, Israel, 2004.
Post-Graduate Training
Post Doctoral Researcher, Cardiology, The Children's Hospital of Philadelphia, Mentor: Robert J. Levy, MD, 2004-2008.
Permanent link
 
> Perelman School of Medicine   > Faculty   > Details

Description of Itmat Expertise

Design of drug, gene, protein and cell delivery systems
Magnetically targeted therapy of arterial restenosis
Nanocarrier-based site-specific gene delivery methods
Prodrug and codrug design
Nanocarrier/prodrug combinations for treating solid tumors

Description of Research Expertise

delivery systems; biodegradable nanocarriers; magnetic targeting of small molecule drugs and biotherapeutics; prodrug and codrug design; targeted therapy of proliferative diseases, arterial restenosis and pediatric solid tumors; neuroblastoma

Selected Publications

I.S. Alferiev, M. Chorny, R.L. Wilensky, R.J. Levy, I. Fishbein: Stent-based gene delivery for coronary disease. Methods in Molecular Biology, accepted; in-print, Aug 2022.

D. Tateiwa, T. Kaito, K. Hashimoto, R. Okada, J. Kodama, J. Kushioka1, Z. Bal, H. Tsukazaki, S. Nakagawa, Y. Ukon, H. Hirai, H. Tian, I. Alferiev, M. Chorny, S. Otsuru, S. Okada, M. Iwamoto: Selective retinoic acid receptor γ antagonist 7C is a potent enhancer of BMP-induced ectopic endochondral bone formation. Frontiers in Cell and Developmental Biology 10: Article 802699, Mar 2022.

I.S. Alferiev, D.T. Guerrero, P. Guan, F. Nguyen, V. Kolla, D. Soberman, B.B. Pressly, I. Fishbein, G.M. Brodeur, M. Chorny: Poloxamer-linked prodrug of a topoisomerase I inhibitor SN22 shows efficacy in models of high-risk neuroblastoma with primary and acquired chemoresistance. The FASEB Journal 36(3): e22213, Mar 2022.

B.B. Pressly, B. Hooshdaran, I.S. Alferiev, M. Chorny, R.J. Levy, S.J. Stachelek, I. Fishbein: Adeno-associated viral vector immobilization and local delivery from bare metal surfaces. Methods in Molecular Biology 2394: 601-616, Feb 2022.

I.S. Alferiev, D.T. Guerrero, D. Soberman, P. Guan, F. Nguyen, V. Kolla, I. Fishbein, B.B. Pressly, G.M. Brodeur, M. Chorny: Nanocarrier-based delivery of SN22 as a tocopheryl oxamate prodrug achieves rapid tumor regression and extends survival in high-risk neuroblastoma models. International Journal of Molecular Sciences 23(3): Article 1752, Feb 2022.

A. Zakharchenko, Y. Xue, S. Keeney, C.A. Rock, I.S. Alferiev, S.J. Stachelek, H. Takano, T. Thomas, C. Nagaswami, A.M. Krieger, M. Chorny, G. Ferrari, R.J. Levy: Poly-2-methyl-2-oxazoline–modified bioprosthetic heart valve leaflets have enhanced biocompatibility and resist structural degeneration. Proceedings of the National Academy of Sciences of the United States of America 119(6): e2120694119, Feb 2022.

I.S. Alferiev, I. Fishbein, R.J. Levy, M. Chorny: Robust chemical strategy for stably labeling polyester-based nanoparticles with BODIPY fluorophores. ACS Applied Polymer Materials 4(2): 1196–1206, Jan 2022.

Y. Polunin, I.S. Alferiev, G.M. Brodeur, A. Voronov*, M. Chorny*: Environment-sensitive polymeric micelles encapsulating SN-38 potently suppress growth of neuroblastoma cells exhibiting intrinsic and acquired drug resistance. ACS Pharmacology & Translational Science 4(1): 240-247, Feb 2021 Notes: * equal contribution.

F. Nguyen, P. Guan, D.T. Guerrero, V. Kolla, K. Naraparaju, L.M. Perry, D. Soberman, B.B. Pressly, I.S. Alferiev*, M. Chorny*, G.M. Brodeur*: Structural optimization and enhanced prodrug-mediated delivery overcomes camptothecin resistance in high-risk solid tumors. Cancer Research 80(19): 4258–4265, Oct 2020 Notes: * equal contribution.

I. Orienti, G. Farruggia, F. Nguyen, P. Guan, N. Calonghi, V. Kolla, M. Chorny, G.M. Brodeur: Nanomicellar lenalidomide–fenretinide combination suppresses tumor growth in an MYCN amplified neuroblastoma tumor. International Journal of Nanomedicine 15: 6873-6886, Sep 2020.

back to top
Last updated: 08/08/2022
The Trustees of the University of Pennsylvania